Cite
HARVARD Citation
Shore, N. et al. (n.d.). Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet oncology. 17 (2), pp. 153-163. [Online].